DK3354267T3 - Stabiliseret sulforaphan - Google Patents
Stabiliseret sulforaphan Download PDFInfo
- Publication number
- DK3354267T3 DK3354267T3 DK18162130.1T DK18162130T DK3354267T3 DK 3354267 T3 DK3354267 T3 DK 3354267T3 DK 18162130 T DK18162130 T DK 18162130T DK 3354267 T3 DK3354267 T3 DK 3354267T3
- Authority
- DK
- Denmark
- Prior art keywords
- sulforaphan
- stabilized
- Prior art date
Links
- SUVMJBTUFCVSAD-UHFFFAOYSA-N Sulforaphane Chemical compound data:image/svg+xml;base64,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 data:image/svg+xml;base64,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 CS(=O)CCCCN=C=S SUVMJBTUFCVSAD-UHFFFAOYSA-N 0.000 title 1
- 0 C1([C](=O)(*)C)CC=CCC1C(=O)CC Chemical compound C1([C](=O)(*)C)CC=CCC1C(=O)CC 0.000 description 8
- UBGLOPPTMBMUQQ-UHFFFAOYSA-N C(N)CCCS(=O)(C)C Chemical compound C(N)CCCS(=O)(C)C UBGLOPPTMBMUQQ-UHFFFAOYSA-N 0.000 description 1
- FMWAVGCSWTYWAX-UHFFFAOYSA-N C1(=CC=CC=C2[C](=O)=CC12)C(=[U])NCCCCS(C)C Chemical compound C1(=CC=CC=C2[C](=O)=CC12)C(=[U])NCCCCS(C)C FMWAVGCSWTYWAX-UHFFFAOYSA-N 0.000 description 1
- JFYXQDRGGGSCAS-UHFFFAOYSA-N C12=CC=CCC=C2C(=O)N(C1=O)CCCCBr Chemical compound C12=CC=CCC=C2C(=O)N(C1=O)CCCCBr JFYXQDRGGGSCAS-UHFFFAOYSA-N 0.000 description 1
- JZDSOQSUCWVBMV-UHFFFAOYSA-N c12C(=O)N(C(=O)c2cccc1)CC Chemical compound c12C(=O)N(C(=O)c2cccc1)CC JZDSOQSUCWVBMV-UHFFFAOYSA-N 0.000 description 1
- VFKAAFLCKKVSAZ-LJQANCHMSA-N c1c2c(C(=O)N(C2=O)CCCC[S@](=C)(=O)C)ccc1 Chemical compound c1c2c(C(=O)N(C2=O)CCCC[S@](=C)(=O)C)ccc1 VFKAAFLCKKVSAZ-LJQANCHMSA-N 0.000 description 1
- GBTBJCDZIYEDAI-UHFFFAOYSA-N c1c2c(ccc1)C(=O)N(C2=O)CCCCSC Chemical compound c1c2c(ccc1)C(=O)N(C2=O)CCCCSC GBTBJCDZIYEDAI-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/26—Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C331/00—Derivatives of thiocyanic acid or of isothiocyanic acid
- C07C331/16—Isothiocyanates
- C07C331/18—Isothiocyanates having isothiocyanate groups bound to acyclic carbon atoms
- C07C331/20—Isothiocyanates having isothiocyanate groups bound to acyclic carbon atoms of a saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C331/00—Derivatives of thiocyanic acid or of isothiocyanic acid
- C07C331/16—Isothiocyanates
- C07C331/26—Isothiocyanates having isothiocyanate groups bound to carbon atoms of rings other than six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/025—Purification; Separation; Stabilisation; Desodorisation of organo-phosphorus compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se)
- C07F9/40—Esters thereof
- C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4006—Esters of acyclic acids which can have further substituents on alkyl
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
- C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
- C08L5/16—Cyclodextrin; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
- C07C2602/42—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing seven carbon atoms
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US88187507P true | 2007-01-23 | 2007-01-23 | |
| EP14166888.9A EP2796140B1 (en) | 2007-01-23 | 2008-01-23 | Stabilized Sulforaphane |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3354267T3 true DK3354267T3 (da) | 2019-08-26 |
Family
ID=39641899
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK14166888.9T DK2796140T3 (da) | 2007-01-23 | 2008-01-23 | Stabiliseret sulforaphan |
| DK18162130.1T DK3354267T3 (da) | 2007-01-23 | 2008-01-23 | Stabiliseret sulforaphan |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK14166888.9T DK2796140T3 (da) | 2007-01-23 | 2008-01-23 | Stabiliseret sulforaphan |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US7879822B2 (da) |
| EP (4) | EP2120969A4 (da) |
| JP (4) | JP2010516766A (da) |
| AU (1) | AU2008209543B2 (da) |
| CA (1) | CA2672971C (da) |
| DK (2) | DK2796140T3 (da) |
| ES (2) | ES2743043T3 (da) |
| HK (1) | HK1199407A1 (da) |
| HR (1) | HRP20191495T1 (da) |
| HU (2) | HUE046151T2 (da) |
| LT (1) | LT3354267T (da) |
| PL (2) | PL3354267T3 (da) |
| PT (1) | PT3354267T (da) |
| SI (1) | SI3354267T1 (da) |
| TR (1) | TR201808561T4 (da) |
| WO (1) | WO2008091608A1 (da) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE046151T2 (hu) * | 2007-01-23 | 2020-02-28 | Pharmagra Labs Inc | Stabilizált szulforafán |
| WO2010065329A2 (en) * | 2008-11-25 | 2010-06-10 | The Board Of Regents Of The University Of Texas System | Nanoparticles for cancer treatment |
| BE1019434A3 (fr) * | 2010-07-23 | 2012-07-03 | Auriga Internat | Stabilisation du sulforaphane. |
| US8933119B2 (en) | 2011-01-03 | 2015-01-13 | The William M. Yarbrough Foundation | Method for treating phytophotodermatitis |
| US10647668B2 (en) | 2011-01-03 | 2020-05-12 | The William M. Yarbrough Foundation | Isothiocyanate functional surfactant and associated method of use |
| US10273205B2 (en) | 2011-01-03 | 2019-04-30 | The William M. Yarbrough Foundation | Isothiocyanate functional surfactants, formulations incorporating isothiocyanate functional surfactants and associated methods for treating biofilms |
| US9962361B2 (en) | 2011-01-03 | 2018-05-08 | The William M. Yarbrough Foundation | Isothiocyanate functional surfactants, formulations incorporating the same, and associated methods of use |
| US10308599B2 (en) | 2011-01-03 | 2019-06-04 | The William M. Yarbrough Foundation | Isothiocyanate functional surfactants, formulations incorporating the same, and associated methods of use |
| US10640464B2 (en) | 2011-01-03 | 2020-05-05 | The William M. Yarbrough Foundation | Use of isothiocyanate functional surfactants as Nrf2 inducers to treat epidermolysis bullosa simplex and related diseases |
| US8865765B2 (en) | 2011-01-12 | 2014-10-21 | The William M. Yarbrough Foundation | Method for treating eczema |
| US9532969B2 (en) | 2011-02-08 | 2017-01-03 | The William M. Yarbrough Foundation | Method for treating psoriasis |
| ES2425294B1 (es) * | 2012-03-09 | 2014-09-02 | Consejo Superior De Investigaciones Científicas (Csic) | Compuestos derivados de sulforafano, método de obtención y su uso médico, alimenticio y cosmético |
| CN102697764A (zh) * | 2012-05-03 | 2012-10-03 | 苏州纳晶医药技术有限公司 | 一种含有异硫氰酸苯乙酯的肠溶固体制剂 |
| WO2013179056A1 (en) * | 2012-06-01 | 2013-12-05 | Pharmagra Labs, Inc. | Sulforaphane isolation and purification |
| US9567405B2 (en) * | 2012-06-01 | 2017-02-14 | Pharmagra Labs, Inc. | Method of synthesising sulforaphane |
| US9839621B2 (en) | 2012-07-26 | 2017-12-12 | The William M. Yarbrough Foundation | Method for treating bladder cancer |
| US10441561B2 (en) | 2012-07-26 | 2019-10-15 | The William M. Yanbrough Foundation | Method for treating benign prostatic hyperplasia (BPH), prostatitis, and prostate cancer |
| US8865772B2 (en) | 2012-07-26 | 2014-10-21 | The William M. Yarbrough Foundation | Method for treating skin cancer |
| US10080734B2 (en) | 2012-07-26 | 2018-09-25 | The William M. Yarbrough Foundation | Method for treating autism and other neurodevelopmental disorders |
| US10335387B2 (en) | 2012-07-26 | 2019-07-02 | The William M. Yarbrough Foundation | Method for treating infectious diseases with isothiocyanate functional compounds |
| US9949943B2 (en) | 2012-07-26 | 2018-04-24 | The William M. Yarbrough Foundation | Method for treating neurodegenerative diseases |
| US10434082B2 (en) | 2012-07-26 | 2019-10-08 | The William M. Yarbrough Foundation | Isothiocyanate functional compounds augmented with secondary antineoplastic medicaments and associated methods for treating neoplasms |
| US10434081B2 (en) | 2012-07-26 | 2019-10-08 | The William M. Yarbrough Foundation | Inhibitors of macrophage migration inhibitory factor |
| DE102014012367B3 (de) * | 2014-08-25 | 2015-08-27 | De Smaakmaker Holding B. V. | Method for determining the concentration of glucoraphanin and / or sulforaphane in a plant |
| CN111902046A (zh) * | 2018-02-02 | 2020-11-06 | 联邦科学技术研究组织 | 保护生物活性物和/或其前体 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US669984A (en) * | 1900-02-06 | 1901-03-19 | Josef Federmann | Spittoon. |
| US673744A (en) * | 1900-08-06 | 1901-05-07 | Pearl M Westerfield | Vending-box. |
| US5458903A (en) * | 1993-01-19 | 1995-10-17 | The Pillsbury Company | High fat biscuit mix and products resulting therefrom |
| US5411986A (en) | 1993-03-12 | 1995-05-02 | The Johns Hopkins University | Chemoprotective isothiocyanates |
| JP3604172B2 (ja) * | 1994-03-22 | 2004-12-22 | 株式会社白元 | 除菌組成物、及び除菌方法 |
| US5589504A (en) | 1994-07-26 | 1996-12-31 | Cornell Research Foundation, Inc. | Treatment of newborn jaundice |
| US6117429A (en) | 1997-08-11 | 2000-09-12 | Weider Nutrition International, Inc | Compositions and treatments for reducing potential unwanted side effects associated with long-term administration of androgenic testosterone precursors |
| US6699849B1 (en) | 1998-02-23 | 2004-03-02 | Cyclops, Ehf. | Cyclodextrin complexes of benzodiazepines |
| FR2776666B1 (fr) * | 1998-03-31 | 2002-09-06 | Commissariat Energie Atomique | INCLUSION COMPLEXES IN ORGANIC ISOTHIOCYANATE CYCLODEXTRINS, IN PARTICULAR BACTERIOSTATICS, BACTERICIDES AND / OR FUNGICIDES OR THEIR NATURAL PRECURSORS, AND THEIR PREPARATION |
| US6048736A (en) * | 1998-04-29 | 2000-04-11 | Kosak; Kenneth M. | Cyclodextrin polymers for carrying and releasing drugs |
| DE60004768T2 (de) | 1999-07-01 | 2004-07-08 | Italfarmaco S.P.A. | COMPLEXES OF PAROXETINE WITH CYCLODEXTRIN OR CYCLODEXTRIN DERIVATIVES |
| US6361812B1 (en) | 1999-11-18 | 2002-03-26 | The Procter & Gamble Co. | Products comprising an isothiocyanate preservative system and methods of their use |
| JP2003518033A (ja) * | 1999-12-20 | 2003-06-03 | コグニス・フランス・ソシエテ・アノニム | 化粧品製剤および／または医薬製剤 |
| US6433011B1 (en) | 2000-03-08 | 2002-08-13 | American Health Foundation | Method for inhibiting formation of aberrant crypt foci in the colon of a mammal |
| JP2002051732A (ja) | 2000-06-12 | 2002-02-19 | Access Business Group Llc | Compositions and methods for correcting dietary phytochemical deficiencies |
| US6812248B2 (en) | 2000-07-05 | 2004-11-02 | John Hopkins University School Of Medicine | Prevention and treatment of degenerative diseases by glutathione and phase II detoxification enzymes |
| CN100522154C (zh) | 2000-08-21 | 2009-08-05 | 杰德W·费伊 | 异硫氰酸酯类化合物在制备治疗螺杆菌感染的药物中的用途 |
| JP2002187842A (ja) * | 2000-12-19 | 2002-07-05 | Toyo Shinyaku:Kk | ケール加工品およびその加工方法 |
| JP2003146803A (ja) * | 2001-11-13 | 2003-05-21 | Carex Inc | 抗菌性粉末組成物およびその製造方法 |
| WO2006105196A2 (en) * | 2005-03-28 | 2006-10-05 | Bioresponse, L.L.C. | Diindolylmethane-based compositions and methods of use thereof for promoting oral mucosal and bone health |
| FR2888235B1 (fr) | 2005-07-07 | 2007-09-14 | Nutrinov Sa | Procede d'extraction de sulforaphane a partir de broyat de crucifere contenant de la glucoraphanine |
| CN101120948A (zh) * | 2006-08-08 | 2008-02-13 | 普文英 | 一种具有化学保护、癌症预防和治疗用途的化合物组合物 |
| HUE046151T2 (hu) * | 2007-01-23 | 2020-02-28 | Pharmagra Labs Inc | Stabilizált szulforafán |
-
2008
- 2008-01-23 HU HUE18162130A patent/HUE046151T2/hu unknown
- 2008-01-23 TR TR2018/08561T patent/TR201808561T4/tr unknown
- 2008-01-23 EP EP08724719A patent/EP2120969A4/en not_active Withdrawn
- 2008-01-23 WO PCT/US2008/000832 patent/WO2008091608A1/en active Application Filing
- 2008-01-23 DK DK14166888.9T patent/DK2796140T3/da active
- 2008-01-23 DK DK18162130.1T patent/DK3354267T3/da active
- 2008-01-23 AU AU2008209543A patent/AU2008209543B2/en active Active
- 2008-01-23 CA CA2672971A patent/CA2672971C/en active Active
- 2008-01-23 ES ES18162130T patent/ES2743043T3/es active Active
- 2008-01-23 HU HUE14166888A patent/HUE039549T2/hu unknown
- 2008-01-23 ES ES14166888.9T patent/ES2674052T3/es active Active
- 2008-01-23 PL PL18162130T patent/PL3354267T3/pl unknown
- 2008-01-23 EP EP12183224A patent/EP2532352A1/en not_active Withdrawn
- 2008-01-23 SI SI200832082T patent/SI3354267T1/sl unknown
- 2008-01-23 JP JP2009547276A patent/JP2010516766A/ja not_active Withdrawn
- 2008-01-23 PT PT18162130T patent/PT3354267T/pt unknown
- 2008-01-23 US US12/009,874 patent/US7879822B2/en active Active
- 2008-01-23 EP EP14166888.9A patent/EP2796140B1/en active Active
- 2008-01-23 LT LTEP18162130.1T patent/LT3354267T/lt unknown
- 2008-01-23 PL PL14166888T patent/PL2796140T3/pl unknown
- 2008-01-23 EP EP18162130.1A patent/EP3354267B1/en active Active
-
2013
- 2013-10-08 JP JP2013210752A patent/JP2014055140A/ja active Pending
-
2014
- 2014-12-29 HK HK14113030.9A patent/HK1199407A1/xx unknown
-
2016
- 2016-02-12 JP JP2016024446A patent/JP6566886B2/ja active Active
-
2017
- 2017-09-11 JP JP2017173723A patent/JP6677688B2/ja active Active
-
2019
- 2019-08-19 HR HRP20191495 patent/HRP20191495T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LU92600I2 (en) | Sovaldi (sofosbuvir) | |
| DK2209856T3 (da) | Aerogelsammensætninger | |
| DK2665193T3 (da) | Styrekanalallokering | |
| DK2205737T3 (da) | Mikromirer | |
| DK2158214T3 (da) | Glukagonanaloger | |
| DK2345653T3 (da) | Morphinanforbindelser | |
| DK2170321T3 (da) | Ormekur-kombination | |
| DK2121534T3 (da) | Enkeltrudelaminater | |
| DK2124668T3 (da) | Hårplejeindretning | |
| BRPI0815042A2 (pt) | Compostos de pirazol | |
| BRPI0813500A2 (pt) | Compostos antivirais | |
| AT540954T (de) | Aminoheterocyclische verbindungen | |
| AT525702T (de) | Erweiterte widgetarchitektur | |
| DK2195058T3 (da) | Laryngealmaske | |
| DK2481796T3 (da) | Glucoamylasevarianter | |
| DK2203551T3 (da) | Bifidobakterieart | |
| AT531723T (de) | Steviolglycosidisomere | |
| BRPI0817238A2 (pt) | Transconector | |
| AT511375T (de) | Getränkeaufbrüheinheit | |
| AT513978T (de) | Drehsteuervorrichtungsandockstation | |
| AT512633T (de) | Wirbelsäulen-verbindungselement | |
| AT544742T (de) | Insektizide arylpyrrolidine | |
| BRPI0814563A2 (pt) | Nanosuperfície | |
| AT530279T (de) | Tangentialschneideeinsatz | |
| DK2514750T3 (da) | Bromphenylsubstituerede thiazolyldihydropyrimidiner |